Platelet P‐selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis
- 21 July 2010
- journal article
- Published by Wiley in Experimental Dermatology
- Vol. 19 (8) , 736-741
Abstract
Please cite this paper as: Platelet P‐selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis. Experimental Dermatology 2010; 19: 736–741.Abstract: Haemostasis‐maintaining platelets are also recognized as important modulators in the regulation of immune response. Activated platelets expressing P‐selectin (CD62P) are involved in the extravasation of leucocytes. This study evaluated platelet P‐selectin expression as a biomarker for cutaneous inflammation. P‐selectin expression was assessed by flow cytometry in 147 successive patients suffering from an inflammatory or infectious skin condition at the day of admission for in‐patient treatment as well as a day prior to demission. Forty‐one patients admitted for allergy testing served as controls. A commercially available ELISA was used in 17 patients to determine soluble P‐selectin in the plasma. In patients with psoriasis, the Psoriasis Area and Severity Index (PASI) was documented as a measure for disease severity. We observed a significant increase in platelet P‐selectin expression in patients with inflammatory or infectious disorders, when compared to the control group (3,01% vs. 1,46%; P < 0.000001). Successful treatment resulted in a significant decrease in P‐selectin expression to the level of the control group. In the case of psoriasis (n = 47), we found highly significant correlation between P‐selectin and PASI (r = 0.51; P < 0.000001), as well as between the change in the PASI and the change in P‐selectin expression (r = 0.4; P = 0.006). Platelet P‐selectin expression as determined by flow cytometry correlated well with the results of soluble P‐selectin, determined by ELISA (r = 0.63; P < 0.01). Thus, platelet P‐selectin expression may be used as an efficacy biomarker to monitor treatment success in psoriasis. As platelet P‐selectin correlates with soluble P‐selectin in patient plasma, which can be measured by ELISA, the latter is feasible also for routine use.Keywords
This publication has 25 references indexed in Scilit:
- Platelet, Not Endothelial, P-Selectin Expression Contributes to Generation of Immunity in Cutaneous Contact HypersensitivityThe American Journal of Pathology, 2010
- β-Defensin-2 Protein Is a Serum Biomarker for Disease Activity in Psoriasis and Reaches Biologically Relevant Concentrations in Lesional SkinPLOS ONE, 2009
- Fucosyltransferase VII-positive, skin-homing T cells in the blood and skin lesions of atopic dermatitis patientsExperimental Dermatology, 2008
- Plasma TGF-β1, TIMP-1, MMP-1 and IL-18 as a combined biomarker of psoriasis activityBiomarkers, 2008
- Elevated Platelet Activation in Patients with Atopic Dermatitis and Psoriasis: Increased Plasma Levels of β-Thromboglobulin and Platelet Factor 4Allergology International, 2008
- Psoriasis patients show signs of insulin resistanceBritish Journal of Dermatology, 2007
- Treatment goals in psoriasisJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2007
- PsoriasisNew England Journal of Medicine, 2005
- Activated, Not Resting, Platelets Increase Leukocyte Rolling in Murine Skin Utilizing a Distinct Set of Adhesion MoleculesJournal of Investigative Dermatology, 2004
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001